Sarclisa

Generic name:isatuximab-irfc
Dosage form: injection, for intravenous use
Drug class:CD38 monoclonal antibodies

Medically reviewed by Judith Stewart, BPharm. Last updated on Sep 13, 2021.

What is Sarclisa?

Sarclisa is a prescription medicine used in combination with:

• the medicines pomalidomide and dexamethasone, to treat adults who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
• the medicines carfilzomib and dexamethasone, to treat adults with multiple myeloma who have already received 1 to 3 lines of treatment and they did not work or are no longer working.

It is not known if Sarclisa is safe and effective in children.

Who should not receive Sarclisa?

You should not receive Sarclisa if you have a history of a severe allergic reaction to isatuximab-irfc or any of the ingredients. See the end of this page for complete list of ingredients.

Before receiving Sarclisa

Before receiving Sarclisa, tell your healthcare provider about all of your medical conditions, including if you:

• have heart problems, if your healthcare provider prescribes Sarclisa in combination with carfilzomib and dexamethasone for you.
• are pregnant or plan to become pregnant. Sarclisa may harm your unborn baby. You should not receive this medicine during pregnancy.
  • Females who are able to become pregnant should use an effective method of birth control during treatment and for 5 months after your last dose. Talk to your healthcare provider about birth control methods that you can use during this time.
    Tell your healthcare provider right away if you think you are pregnant or become pregnant during treatment.
• are breastfeeding or plan to breastfeed. It is not known if Sarclisa passes into your breast milk. You should not breastfeed during treatment.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.